Mitchell J. Frederick

11.4k total citations
79 papers, 3.2k citations indexed

About

Mitchell J. Frederick is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Mitchell J. Frederick has authored 79 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Molecular Biology, 38 papers in Oncology and 24 papers in Cancer Research. Recurrent topics in Mitchell J. Frederick's work include Cancer-related Molecular Pathways (24 papers), RNA modifications and cancer (15 papers) and Cancer-related gene regulation (8 papers). Mitchell J. Frederick is often cited by papers focused on Cancer-related Molecular Pathways (24 papers), RNA modifications and cancer (15 papers) and Cancer-related gene regulation (8 papers). Mitchell J. Frederick collaborates with scholars based in United States, Japan and China. Mitchell J. Frederick's co-authors include Gary L. Clayman, Ying C. Henderson, Adel K. El‐Naggar, Jeffrey N. Myers, Curtis R. Pickering, Arumugam Jayakumar, Mary Wang, Kenji Mitsudo, Mei Zhao and Vlad C. Sandulache and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and The Journal of Immunology.

In The Last Decade

Mitchell J. Frederick

73 papers receiving 3.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mitchell J. Frederick United States	31	1.6k	1.3k	644	605	321	79	3.2k
Chi Man Tsang Hong Kong	29	1.2k 0.8×	1.7k 1.2×	946 1.5×	536 0.9×	106 0.3×	48	3.1k
Dolly P. Huang Hong Kong	40	2.3k 1.4×	2.4k 1.8×	1.4k 2.1×	510 0.8×	352 1.1×	65	4.8k
Paul G. Murray United Kingdom	39	2.0k 1.3×	2.9k 2.2×	1.1k 1.7×	1.1k 1.9×	257 0.8×	92	5.4k
Lars Uhlin‐Hansen Norway	27	1.1k 0.7×	688 0.5×	713 1.1×	575 1.0×	119 0.4×	56	2.5k
Bhavna Kumar United States	32	1.6k 1.0×	1.4k 1.1×	822 1.3×	367 0.6×	175 0.5×	65	3.7k
Régis Costello France	33	872 0.5×	1.3k 1.0×	309 0.5×	2.0k 3.4×	139 0.4×	153	3.9k
G. Bea A. Wisman Netherlands	38	1.8k 1.1×	868 0.7×	719 1.1×	483 0.8×	188 0.6×	94	3.4k
Antonella Ravaggi Italy	34	783 0.5×	833 0.6×	421 0.7×	967 1.6×	197 0.6×	104	3.3k
Wa Xian United States	31	1.5k 0.9×	774 0.6×	658 1.0×	317 0.5×	244 0.8×	59	3.7k
Thomas J. Belbin United States	30	1.7k 1.0×	477 0.4×	681 1.1×	191 0.3×	143 0.4×	60	2.5k

Countries citing papers authored by Mitchell J. Frederick

Since Specialization

Citations

This map shows the geographic impact of Mitchell J. Frederick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mitchell J. Frederick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mitchell J. Frederick more than expected).

Fields of papers citing papers by Mitchell J. Frederick

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mitchell J. Frederick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mitchell J. Frederick. The network helps show where Mitchell J. Frederick may publish in the future.

Co-authorship network of co-authors of Mitchell J. Frederick

This figure shows the co-authorship network connecting the top 25 collaborators of Mitchell J. Frederick. A scholar is included among the top collaborators of Mitchell J. Frederick based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mitchell J. Frederick. Mitchell J. Frederick is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Frederick, Mitchell J., Patricia Castro, Amy Hamlin, et al.. (2025). Reliable RNA-seq analysis from FFPE specimens as a means to accelerate cancer-related health disparities research. PLoS ONE. 20(4). e0321631–e0321631.

Patel, Rutulkumar, Lixia Luo, Yan Ma, et al.. (2025). Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research. 31(19). 4184–4195.

Pifer, Phillip M., Liangpeng Yang, Manish Kumar, et al.. (2023). FAK Drives Resistance to Therapy in HPV-Negative Head and Neck Cancer in a p53-Dependent Manner. Clinical Cancer Research. 30(1). 187–197. 13 indexed citations

Osman, Abdullah A., Emre Arslan, Chieko Michikawa, et al.. (2023). Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research. 29(7). 1344–1359. 32 indexed citations

Ahmed, Kazi Mokim, Ratna Veeramachaneni, Defeng Deng, et al.. (2022). Glutathione peroxidase 2 is a metabolic driver of the tumor immune microenvironment and immune checkpoint inhibitor response. Journal for ImmunoTherapy of Cancer. 10(8). e004752–e004752. 29 indexed citations

Sambandam, Vaishnavi, Hongyun Zhao, Tuhina Mazumdar, et al.. (2022). Sustained Aurora Kinase B Expression Confers Resistance to PI3K Inhibition in Head and Neck Squamous Cell Carcinoma. Cancer Research. 82(23). 4444–4456. 8 indexed citations

Lindemann, Antje, Ameeta A. Patel, Lin Tang, et al.. (2021). Combined Inhibition of Rad51 and Wee1 Enhances Cell Killing in HNSCC Through Induction of Apoptosis Associated With Excessive DNA Damage and Replication Stress. Molecular Cancer Therapeutics. 20(7). 1257–1269. 18 indexed citations

Frederick, Mitchell J., et al.. (2020). High expression of oxidative phosphorylation genes predicts improved survival in squamous cell carcinomas of the head and neck and lung. Scientific Reports. 10(1). 6380–6380. 30 indexed citations

Sambandam, Vaishnavi, Mitchell J. Frederick, Li Shen, et al.. (2019). PDK1 Mediates NOTCH1 -Mutated Head and Neck Squamous Carcinoma Vulnerability to Therapeutic PI3K/mTOR Inhibition. Clinical Cancer Research. 25(11). 3329–3340. 42 indexed citations

10.

Zhang, Jiexin, Li Shen, Xiayu Rao, et al.. (2017). CDKN2A/p16 Deletion in Head and Neck Cancer Cells Is Associated with CDK2 Activation, Replication Stress, and Vulnerability to CHK1 Inhibition. Cancer Research. 78(3). 781–797. 34 indexed citations

11.

Tanaka, Noriaki, Ameeta A. Patel, Jiping Wang, et al.. (2015). Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins. Clinical Cancer Research. 21(21). 4831–4844. 46 indexed citations

12.

Pickering, Curtis R., Jiexin Zhang, David M. Neskey, et al.. (2014). Squamous Cell Carcinoma of the Oral Tongue in Young Non-Smokers Is Genomically Similar to Tumors in Older Smokers. Clinical Cancer Research. 20(14). 3842–3848. 118 indexed citations

13.

Osman, Abdullah A., Marcus M. Monroe, Marcus V. Ortega Alves, et al.. (2014). Wee-1 Kinase Inhibition Overcomes Cisplatin Resistance Associated with High-Risk TP53 Mutations in Head and Neck Cancer through Mitotic Arrest Followed by Senescence. Molecular Cancer Therapeutics. 14(2). 608–619. 88 indexed citations

14.

Alves, Marcus V. Ortega, Curtis R. Pickering, Abdullah A. Osman, et al.. (2013). Chk1/2 Inhibition Overcomes the Cisplatin Resistance of Head and Neck Cancer Cells Secondary to the Loss of Functional p53. Molecular Cancer Therapeutics. 12(9). 1860–1873. 95 indexed citations

15.

Pierobon, Mariaelena, et al.. (2013). Reverse Phase Protein Microarrays and Their Utility in Drug Development. Methods in molecular biology. 986. 187–214. 10 indexed citations

16.

Takahashi, Yoko, Michael E. Kupferman, Diana Bell, et al.. (2012). Establishment and Characterization of Novel Cell Lines from Sinonasal Undifferentiated Carcinoma. Clinical Cancer Research. 18(22). 6178–6187. 23 indexed citations

17.

Chen, Yunyun, Daisuke Sano, Mitchell J. Frederick, et al.. (2011). Targeted Therapy of VEGFR2 and EGFR Significantly Inhibits Growth of Anaplastic Thyroid Cancer in an Orthotopic Murine Model. Clinical Cancer Research. 17(8). 2281–2291. 68 indexed citations

18.

Henderson, Ying C., Mitchell J. Frederick, Arumugam Jayakumar, et al.. (2006). Human LBP-32/MGR is a Repressor of the P450scc in Human Choriocarcinoma Cell Line JEG-3. Placenta. 28(2-3). 152–160. 12 indexed citations

19.

Shellenberger, Thomas D., Mary Wang, Arumugam Jayakumar, et al.. (2004). BRAK/CXCL14 Is a Potent Inhibitor of Angiogenesis and a Chemotactic Factor for Immature Dendritic Cells. Cancer Research. 64(22). 8262–8270. 204 indexed citations

20.

Frank, Douglas K., Ta Jen Liu, Mitchell J. Frederick, & Gary L. Clayman. (1998). Combination E2F-1 and p53 gene transfer does not enhance growth inhibition in human squamous cell carcinoma of the head and neck.. PubMed. 4(9). 2265–72. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact